AR128540A1 - Moléculas de unión anti-tdp-43 humanizadas y usos de las mismas - Google Patents
Moléculas de unión anti-tdp-43 humanizadas y usos de las mismasInfo
- Publication number
- AR128540A1 AR128540A1 ARP230100367A ARP230100367A AR128540A1 AR 128540 A1 AR128540 A1 AR 128540A1 AR P230100367 A ARP230100367 A AR P230100367A AR P230100367 A ARP230100367 A AR P230100367A AR 128540 A1 AR128540 A1 AR 128540A1
- Authority
- AR
- Argentina
- Prior art keywords
- tdp
- disease
- seq
- humanized
- amino acid
- Prior art date
Links
- 230000027455 binding Effects 0.000 title abstract 10
- 102100040347 TAR DNA-binding protein 43 Human genes 0.000 abstract 15
- 101710150875 TAR DNA-binding protein 43 Proteins 0.000 abstract 13
- 201000011240 Frontotemporal dementia Diseases 0.000 abstract 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 9
- 230000035772 mutation Effects 0.000 abstract 9
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 6
- 201000010099 disease Diseases 0.000 abstract 6
- 208000024827 Alzheimer disease Diseases 0.000 abstract 5
- 208000004051 Chronic Traumatic Encephalopathy Diseases 0.000 abstract 4
- 208000018737 Parkinson disease Diseases 0.000 abstract 4
- 102100026145 Transitional endoplasmic reticulum ATPase Human genes 0.000 abstract 4
- 108010027273 Valosin Containing Protein Proteins 0.000 abstract 4
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 abstract 4
- 208000017004 dementia pugilistica Diseases 0.000 abstract 4
- 208000002569 Machado-Joseph Disease Diseases 0.000 abstract 3
- 208000036834 Spinocerebellar ataxia type 3 Diseases 0.000 abstract 3
- 208000035475 disorder Diseases 0.000 abstract 3
- 102000039446 nucleic acids Human genes 0.000 abstract 3
- 108020004707 nucleic acids Proteins 0.000 abstract 3
- 150000007523 nucleic acids Chemical class 0.000 abstract 3
- 208000011403 Alexander disease Diseases 0.000 abstract 2
- 102100022987 Angiogenin Human genes 0.000 abstract 2
- 208000014644 Brain disease Diseases 0.000 abstract 2
- 206010012289 Dementia Diseases 0.000 abstract 2
- 206010067889 Dementia with Lewy bodies Diseases 0.000 abstract 2
- 102100036912 Desmin Human genes 0.000 abstract 2
- 108010044052 Desmin Proteins 0.000 abstract 2
- 208000032274 Encephalopathy Diseases 0.000 abstract 2
- 208000002339 Frontotemporal Lobar Degeneration Diseases 0.000 abstract 2
- 101000989058 Homo sapiens Immunoglobulin heavy variable 1-69-2 Proteins 0.000 abstract 2
- 101001047627 Homo sapiens Immunoglobulin kappa variable 2-28 Proteins 0.000 abstract 2
- 101000891092 Homo sapiens TAR DNA-binding protein 43 Proteins 0.000 abstract 2
- 102100029422 Immunoglobulin heavy variable 1-69-2 Human genes 0.000 abstract 2
- 102100022950 Immunoglobulin kappa variable 2-28 Human genes 0.000 abstract 2
- 201000002832 Lewy body dementia Diseases 0.000 abstract 2
- 208000026072 Motor neurone disease Diseases 0.000 abstract 2
- 208000021642 Muscular disease Diseases 0.000 abstract 2
- 201000009623 Myopathy Diseases 0.000 abstract 2
- 102100037632 Progranulin Human genes 0.000 abstract 2
- 208000036278 TDP-43 proteinopathy Diseases 0.000 abstract 2
- 208000030886 Traumatic Brain injury Diseases 0.000 abstract 2
- 230000005856 abnormality Effects 0.000 abstract 2
- 108010072788 angiogenin Proteins 0.000 abstract 2
- 239000000427 antigen Substances 0.000 abstract 2
- 102000036639 antigens Human genes 0.000 abstract 2
- 108091007433 antigens Proteins 0.000 abstract 2
- 210000005045 desmin Anatomy 0.000 abstract 2
- 239000012634 fragment Substances 0.000 abstract 2
- 229940127121 immunoconjugate Drugs 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 208000005264 motor neuron disease Diseases 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 208000001282 primary progressive aphasia Diseases 0.000 abstract 2
- 230000009529 traumatic brain injury Effects 0.000 abstract 2
- 102000043334 C9orf72 Human genes 0.000 abstract 1
- 108700030955 C9orf72 Proteins 0.000 abstract 1
- 101150014718 C9orf72 gene Proteins 0.000 abstract 1
- 208000011990 Corticobasal Degeneration Diseases 0.000 abstract 1
- 102000052510 DNA-Binding Proteins Human genes 0.000 abstract 1
- 108700020911 DNA-Binding Proteins Proteins 0.000 abstract 1
- 201000010374 Down Syndrome Diseases 0.000 abstract 1
- UQHGAYSULGRWRG-WHFBIAKZSA-N Glu-Ser Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](CO)C(O)=O UQHGAYSULGRWRG-WHFBIAKZSA-N 0.000 abstract 1
- 206010063629 Hippocampal sclerosis Diseases 0.000 abstract 1
- 101000839665 Homo sapiens Immunoglobulin heavy variable 3-43 Proteins 0.000 abstract 1
- 101000989062 Homo sapiens Immunoglobulin heavy variable 5-51 Proteins 0.000 abstract 1
- 101001047626 Homo sapiens Immunoglobulin kappa variable 2-24 Proteins 0.000 abstract 1
- 101001047625 Homo sapiens Immunoglobulin kappa variable 2-40 Proteins 0.000 abstract 1
- 101001008323 Homo sapiens Immunoglobulin kappa variable 2D-28 Proteins 0.000 abstract 1
- 101001008293 Homo sapiens Immunoglobulin kappa variable 2D-40 Proteins 0.000 abstract 1
- 101000604674 Homo sapiens Immunoglobulin kappa variable 4-1 Proteins 0.000 abstract 1
- 208000023105 Huntington disease Diseases 0.000 abstract 1
- 102100028315 Immunoglobulin heavy variable 3-43 Human genes 0.000 abstract 1
- 102100029414 Immunoglobulin heavy variable 5-51 Human genes 0.000 abstract 1
- 102100022947 Immunoglobulin kappa variable 2-24 Human genes 0.000 abstract 1
- 102100022948 Immunoglobulin kappa variable 2-40 Human genes 0.000 abstract 1
- 102100027459 Immunoglobulin kappa variable 2D-28 Human genes 0.000 abstract 1
- 102100027409 Immunoglobulin kappa variable 2D-40 Human genes 0.000 abstract 1
- 102100038198 Immunoglobulin kappa variable 4-1 Human genes 0.000 abstract 1
- 102100038894 Myotilin Human genes 0.000 abstract 1
- 101710100281 Myotilin Proteins 0.000 abstract 1
- 201000009110 Oculopharyngeal muscular dystrophy Diseases 0.000 abstract 1
- 208000010191 Osteitis Deformans Diseases 0.000 abstract 1
- 208000027067 Paget disease of bone Diseases 0.000 abstract 1
- 201000004316 Perry syndrome Diseases 0.000 abstract 1
- 208000000609 Pick Disease of the Brain Diseases 0.000 abstract 1
- 108010012809 Progranulins Proteins 0.000 abstract 1
- 208000034189 Sclerosis Diseases 0.000 abstract 1
- 102000044159 Ubiquitin Human genes 0.000 abstract 1
- 108090000848 Ubiquitin Proteins 0.000 abstract 1
- 230000003542 behavioural effect Effects 0.000 abstract 1
- 208000016738 bone Paget disease Diseases 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 abstract 1
- 210000000349 chromosome Anatomy 0.000 abstract 1
- 238000003745 diagnosis Methods 0.000 abstract 1
- 239000003085 diluting agent Substances 0.000 abstract 1
- 239000013604 expression vector Substances 0.000 abstract 1
- 210000003000 inclusion body Anatomy 0.000 abstract 1
- 201000008319 inclusion body myositis Diseases 0.000 abstract 1
- 208000002086 myofibrillar myopathy Diseases 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
- 229920000155 polyglutamine Polymers 0.000 abstract 1
- 108010040003 polyglutamine Proteins 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 238000003259 recombinant expression Methods 0.000 abstract 1
- 210000003934 vacuole Anatomy 0.000 abstract 1
- 239000013598 vector Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Neurosurgery (AREA)
- Life Sciences & Earth Sciences (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Hospice & Palliative Care (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Psychiatry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La presente invención pertenece al campo de las proteínas de unión a ADN de respuesta transactiva con un peso molecular de 43 kDa (TARDB o también TDP-43). Se describen moléculas de unión a TDP-43 humanizadas específicas, en particular a anticuerpos anti-TDP-43 humanizadas o un fragmento de unión a antígeno o un derivado de los mismos y sus usos. Asimismo se proveen medios y métodos para diagnosticar, prevenir, aliviar y/o tratar una enfermedad, un trastorno y/o una anomalía asociada con agregados de TDP-43 que incluye, pero en un sentido no taxativo, demencia frontotemporal (FTD), esclerosis lateral amiotrófica (ALS), enfermedad de Alzheimer (AD), enfermedad de Parkinson (PD), encefalopatía traumática crónica (CTE) y encefalopatía TDP-43 con predominio límbico relacionada con la edad (LATE). Reivindicación 1: Una molécula de unión a TDP-43 humanizada, en particular un anticuerpo anti-TDP-43 humanizado o un fragmento de unión a antígeno del mismo, que comprende: a. una VH-CDR1 que comprende la secuencia de aminoácidos de la SEQ ID Nº 21; b. una VH-CDR2 seleccionada entre las secuencias de aminoácidos de la SEQ ID Nº 22, SEQ ID Nº 82, SEQ ID Nº 92; SEQ ID Nº 102, SEQ ID Nº 112 o la SEQ ID Nº 122; c. una VH-CDR3 que comprende la secuencia de aminoácidos ES (Glu-Ser); d. una VL-CDR1 seleccionada entre las secuencias de aminoácidos de la SEQ ID Nº 25 o la SEQ ID Nº 85; e. una VL-CDR2 seleccionada de la secuencia de aminoácidos de la SEQ ID Nº 16; f. una VL-CDR3 seleccionada entre las secuencias de aminoácidos de la SEQ ID Nº 27 o la SEQ ID Nº 87; y g. un marco aceptor de un dominio variable de la cadena pesada (VH) que se selecciona del grupo que consiste en IGHV1-69-2, IGHV5-51 o IGHV3-43, preferiblemente IGHV1-69-2; y/o h. un marco aceptor de un dominio variable de la cadena liviana (VL) que se selecciona del grupo que consiste en IGKV2-28, IGKV2-24, IGKV2D-28, IGKV2-40, IGKV2D-40 o IGKV4-1, preferiblemente IGKV2-28. Reivindicación 38: Una composición farmacéutica, que comprende la molécula de unión a la TDP-43 humanizada de cualquiera de las reivindicaciones 1 a 29, o un inmunoconjugado de cualquiera de las reivindicaciones 30 a 36 y un vehículo y/o excipiente y/o diluyente farmacéuticamente aceptable. Reivindicación 45: La molécula de unión a una TDP-43 humanizada o un inmunoconjugado o una molécula de unión marcada o una composición farmacéutica para usar de acuerdo con cualquiera de las reivindicaciones 40, 42 o 44, donde la enfermedad, trastorno y/o la anomalía asociada con TDP-43, o con una proteinopatía por TDP-43, es demencia frontotemporal (FTD, tal como esporádica o familiar con o sin enfermedad de neuronas motoras (MND), con una mutación de progranulina (GRN), con mutaciones C9orf72, con una mutación TARDBP, con una mutación de proteína que contiene valosina (VCP), ligada al cromosoma 9p, degeneración corticobasal, degeneración lobular frontotemporal (FTLD) con inclusiones de TDP-43 ubiquitina-positivas (FTLD-TDP), enfermedad argirofílica granulosa, enfermedad de Pick, variante semántica de afasia progresiva primaria (svPPA), variante de comportamiento de FTD (bvFTD), variante no fluida de la afasia progresiva primaria (nfvPPA) y semejantes), esclerosis lateral amiotrófica (ALS, tal como ALS esporádica, con una mutación TARDBP, con una mutación de angiogenina (ANG)), enfermedad de Alexander (AxD), encefalopatía TDP-43 con predominio límbico, relacionada con la edad (LATE), encefalopatía traumática crónica (CTE), síndrome de Perry, enfermedad de Alzheimer (AD, que incluye las formas esporádica y familiar de AD), síndrome de Down, demencia familiar británica, enfermedades de la poliglutamina (enfermedad de Huntington y ataxia espinocerebelosa tipo 3 (SCA3; también conocida como enfermedad de Machado Joseph)), demencia con esclerosis del hipocampo y miopatías (miositis por cuerpos de inclusión esporádica, miopatía por cuerpos de inclusión con una mutación en la proteína que contiene valosina ((VCP); también la enfermedad ósea de Paget y demencia frontotemporal), distrofia muscular oculofaríngea con vacuolas ribeteadas, miopatías miofibrilares con mutaciones en el gen de miotilina (MYOT) o mutaciones en el gen que codifica desmina (DES)), lesión de cerebro traumática (TBI), demencia con cuerpos de Lewy (DLB) o enfermedad de Parkinson (PD). Reivindicación 54: Una molécula de ácido nucleico, que codifica la molécula de unión a TDP-43 humanizada de cualquiera de las reivindicaciones 1 a 29. Reivindicación 59: Un vector de expresión recombinante, que comprende el ácido nucleico de cualquiera de las reivindicaciones 54 a 58. Reivindicación 60: Una célula huésped, que comprende el ácido nucleico de cualquiera de las reivindicaciones 54 a 58 y/o el vector de la reivindicación 59. Reivindicación 66: Un kit para el diagnóstico de una enfermedad, un trastorno y/o una anomalía asociada con una TDP-43, o con una proteinopatía TDP-43, o para usar de acuerdo con cualquiera de las reivindicaciones 39 a 49, o para usar en un método de cualquiera de las reivindicaciones 50 a 53, que comprende una molécula de unión a una TDP-43 humanizada de acuerdo con cualquiera de las reivindicaciones 1 a 29.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP22157150 | 2022-02-16 | ||
EP22177361 | 2022-06-06 | ||
EP23152958 | 2023-01-23 | ||
EP23153165 | 2023-01-24 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR128540A1 true AR128540A1 (es) | 2024-05-22 |
Family
ID=85239102
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP230100367A AR128540A1 (es) | 2022-02-16 | 2023-02-16 | Moléculas de unión anti-tdp-43 humanizadas y usos de las mismas |
Country Status (3)
Country | Link |
---|---|
AR (1) | AR128540A1 (es) |
TW (1) | TW202342519A (es) |
WO (1) | WO2023156549A1 (es) |
Family Cites Families (75)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
EP0307434B2 (en) | 1987-03-18 | 1998-07-29 | Scotgen Biopharmaceuticals, Inc. | Altered antibodies |
US5004697A (en) | 1987-08-17 | 1991-04-02 | Univ. Of Ca | Cationized antibodies for delivery through the blood-brain barrier |
US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
US5959177A (en) | 1989-10-27 | 1999-09-28 | The Scripps Research Institute | Transgenic plants expressing assembled secretory antibodies |
US5112596A (en) | 1990-04-23 | 1992-05-12 | Alkermes, Inc. | Method for increasing blood-brain barrier permeability by administering a bradykinin agonist of blood-brain barrier permeability |
US5268164A (en) | 1990-04-23 | 1993-12-07 | Alkermes, Inc. | Increasing blood-brain barrier permeability with permeabilizer peptides |
GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
US5877397A (en) | 1990-08-29 | 1999-03-02 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
LU91067I2 (fr) | 1991-06-14 | 2004-04-02 | Genentech Inc | Trastuzumab et ses variantes et dérivés immuno chimiques y compris les immotoxines |
CA2116774C (en) | 1991-09-19 | 2003-11-11 | Paul J. Carter | Expression in e. coli antibody fragments having at least a cysteine present as a free thiol. use for the production of bifunctional f(ab') 2 antibodies |
ATE463573T1 (de) | 1991-12-02 | 2010-04-15 | Medimmune Ltd | Herstellung von autoantikörpern auf phagenoberflächen ausgehend von antikörpersegmentbibliotheken |
AU677216B2 (en) | 1992-07-27 | 1997-04-17 | Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The | Targeting of liposomes to the blood-brain barrier |
FR2707189B1 (fr) | 1993-07-09 | 1995-10-13 | Gradient Ass | Procédé de traitement de résidus de combustion et installation de mise en Óoeuvre dudit procédé. |
US5789199A (en) | 1994-11-03 | 1998-08-04 | Genentech, Inc. | Process for bacterial production of polypeptides |
US5840523A (en) | 1995-03-01 | 1998-11-24 | Genetech, Inc. | Methods and compositions for secretion of heterologous polypeptides |
US6267958B1 (en) | 1995-07-27 | 2001-07-31 | Genentech, Inc. | Protein formulation |
GB9603256D0 (en) | 1996-02-16 | 1996-04-17 | Wellcome Found | Antibodies |
US6171586B1 (en) | 1997-06-13 | 2001-01-09 | Genentech, Inc. | Antibody formulation |
ES2244066T3 (es) | 1997-06-24 | 2005-12-01 | Genentech, Inc. | Procedimiento y composiciones de glicoproteinas galactosiladas. |
US6040498A (en) | 1998-08-11 | 2000-03-21 | North Caroline State University | Genetically engineered duckweed |
WO1999022764A1 (en) | 1997-10-31 | 1999-05-14 | Genentech, Inc. | Methods and compositions comprising glycoprotein glycoforms |
ES2434961T5 (es) | 1998-04-20 | 2018-01-18 | Roche Glycart Ag | Ingeniería de glicosilación de anticuerpos para mejorar la citotoxicidad celular dependiente del anticuerpo |
US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
PL209786B1 (pl) | 1999-01-15 | 2011-10-31 | Genentech Inc | Przeciwciało zawierające wariant regionu Fc ludzkiej IgG1, przeciwciało wiążące czynnik wzrostu śródbłonka naczyń oraz immunoadhezyna |
DK2275540T3 (en) | 1999-04-09 | 2016-05-09 | Kyowa Hakko Kirin Co Ltd | Method for controlling the activity of immunologically functional molecule. |
DE60022369T2 (de) | 1999-10-04 | 2006-05-18 | Medicago Inc., Sainte Foy | Verfahren zur regulation der transkription von fremden genen in gegenwart von stickstoff |
US7125978B1 (en) | 1999-10-04 | 2006-10-24 | Medicago Inc. | Promoter for regulating expression of foreign genes |
US7504256B1 (en) | 1999-10-19 | 2009-03-17 | Kyowa Hakko Kogyo Co., Ltd. | Process for producing polypeptide |
US6514221B2 (en) | 2000-07-27 | 2003-02-04 | Brigham And Women's Hospital, Inc. | Blood-brain barrier opening |
US7129084B2 (en) | 2000-08-03 | 2006-10-31 | Therapeutic Human Polyclonals, Inc. | Production of humanized antibodies in transgenic animals |
US20020065259A1 (en) | 2000-08-30 | 2002-05-30 | Schatzberg Alan F. | Glucocorticoid blocking agents for increasing blood-brain barrier permeability |
DK1332209T3 (da) | 2000-09-08 | 2010-03-29 | Univ Zuerich | Samlinger af repeatproteiner indeholdende repeatmoduler |
EA013563B1 (ru) | 2000-10-06 | 2010-06-30 | Киова Хакко Кирин Ко., Лтд. | Трансгенное животное, продуцирующее антитела с измененными углеводными цепями, способ получения антител и содержащее антитела лекарственное средство |
US6946292B2 (en) | 2000-10-06 | 2005-09-20 | Kyowa Hakko Kogyo Co., Ltd. | Cells producing antibody compositions with increased antibody dependent cytotoxic activity |
US7064191B2 (en) | 2000-10-06 | 2006-06-20 | Kyowa Hakko Kogyo Co., Ltd. | Process for purifying antibody |
EP2141243A3 (en) | 2000-10-16 | 2010-01-27 | Brystol-Myers Squibb Company | Protein scaffolds for antibody mimics and other binding proteins |
US7034036B2 (en) | 2000-10-30 | 2006-04-25 | Pain Therapeutics, Inc. | Inhibitors of ABC drug transporters at the blood-brain barrier |
US20030157561A1 (en) | 2001-11-19 | 2003-08-21 | Kolkman Joost A. | Combinatorial libraries of monomer domains |
DE10121982B4 (de) | 2001-05-05 | 2008-01-24 | Lts Lohmann Therapie-Systeme Ag | Nanopartikel aus Protein mit gekoppeltem Apolipoprotein E zur Überwindung der Blut-Hirn-Schranke und Verfahren zu ihrer Herstellung |
KR20040054669A (ko) | 2001-08-03 | 2004-06-25 | 글리카트 바이오테크놀로지 아게 | 항체 의존적 세포 독성이 증가된 항체 글리코실화 변이체 |
EP1443961B1 (en) | 2001-10-25 | 2009-05-06 | Genentech, Inc. | Glycoprotein compositions |
US20040093621A1 (en) | 2001-12-25 | 2004-05-13 | Kyowa Hakko Kogyo Co., Ltd | Antibody composition which specifically binds to CD20 |
US20030162695A1 (en) | 2002-02-27 | 2003-08-28 | Schatzberg Alan F. | Glucocorticoid blocking agents for increasing blood-brain barrier permeability |
JP4832719B2 (ja) | 2002-04-09 | 2011-12-07 | 協和発酵キリン株式会社 | FcγRIIIa多型患者に適応する抗体組成物含有医薬 |
EP1498485A4 (en) | 2002-04-09 | 2006-09-06 | Kyowa Hakko Kogyo Kk | CELLS WITH MODIFIED GENOM |
CA2481658A1 (en) | 2002-04-09 | 2003-10-16 | Kyowa Hakko Kogyo Co., Ltd. | Method of enhancing of binding activity of antibody composition to fcy receptor iiia |
JPWO2003085118A1 (ja) | 2002-04-09 | 2005-08-11 | 協和醗酵工業株式会社 | 抗体組成物の製造方法 |
JPWO2003084569A1 (ja) | 2002-04-09 | 2005-08-11 | 協和醗酵工業株式会社 | 抗体組成物含有医薬 |
AU2003236020B2 (en) | 2002-04-09 | 2009-03-19 | Kyowa Hakko Kirin Co., Ltd. | Cell with depression or deletion of the activity of protein participating in GDP-fucose transport |
CA2791165C (en) | 2002-12-03 | 2015-02-24 | Blanchette Rockefeller Neurosciences Institute | A conjugate comprising cholesterol linked to tetracycline |
KR20070055625A (ko) | 2002-12-16 | 2007-05-30 | 제넨테크, 인크. | 이뮤노글로불린 변이체 및 이들의 용도 |
US20060104968A1 (en) | 2003-03-05 | 2006-05-18 | Halozyme, Inc. | Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases |
US7871607B2 (en) | 2003-03-05 | 2011-01-18 | Halozyme, Inc. | Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases |
WO2005025511A2 (en) | 2003-09-10 | 2005-03-24 | Cedars-Sinai Medical Center | Potassium channel mediated delivery of agents through the blood-brain barrier |
WO2005035586A1 (ja) | 2003-10-08 | 2005-04-21 | Kyowa Hakko Kogyo Co., Ltd. | 融合蛋白質組成物 |
CA2542125A1 (en) | 2003-10-09 | 2005-04-21 | Kyowa Hakko Kogyo Co., Ltd. | Process for producing antibody composition by using rna inhibiting the function of .alpha.1,6-fucosyltransferase |
EP1675878A2 (en) | 2003-10-24 | 2006-07-05 | Avidia, Inc. | Ldl receptor class a and egf domain monomers and multimers |
SG10201504094SA (en) | 2003-11-05 | 2015-06-29 | Roche Glycart Ag | Cd20 antibodies with increased fc receptor binding affinity and effector function |
JPWO2005053742A1 (ja) | 2003-12-04 | 2007-06-28 | 協和醗酵工業株式会社 | 抗体組成物を含有する医薬 |
RU2368622C2 (ru) | 2004-04-13 | 2009-09-27 | Ф.Хоффманн-Ля Рош Аг | Антитела к р-селектину |
TWI380996B (zh) | 2004-09-17 | 2013-01-01 | Hoffmann La Roche | 抗ox40l抗體 |
WO2006034488A2 (en) | 2004-09-23 | 2006-03-30 | Genentech, Inc. | Cysteine engineered antibodies and conjugates |
JO3000B1 (ar) | 2004-10-20 | 2016-09-05 | Genentech Inc | مركبات أجسام مضادة . |
US20080226635A1 (en) | 2006-12-22 | 2008-09-18 | Hans Koll | Antibodies against insulin-like growth factor I receptor and uses thereof |
WO2008151055A1 (en) | 2007-06-01 | 2008-12-11 | Mayo Foundation For Medical Education And Research | Diagnosing neurodegenerative diseases |
EP2603233A1 (en) | 2010-08-12 | 2013-06-19 | AC Immune S.A. | Vaccine engineering |
CA2813833C (en) | 2010-10-26 | 2020-09-22 | Ac Immune S.A. | Liposome-based construct comprising a peptide modified through hydrophobic moieties |
KR102032080B1 (ko) | 2011-10-28 | 2019-10-15 | 바이오겐 인터내셔널 뉴로사이언스 게엠베하 | Tdp-43 특이적 결합 분자 |
CN104284675B (zh) | 2012-03-16 | 2017-07-18 | 科瓦根股份公司 | 具有抗肿瘤活性的新颖结合分子 |
JP2022533432A (ja) | 2019-05-23 | 2022-07-22 | エイシー イミューン ソシエテ アノニム | 抗tdp-43結合分子およびその使用 |
AR123254A1 (es) | 2020-08-14 | 2022-11-16 | Ac Immune Sa | Moléculas de unión anti-tdp-43 humanizadas y usos de las mismas |
-
2023
- 2023-02-16 AR ARP230100367A patent/AR128540A1/es unknown
- 2023-02-16 TW TW112105586A patent/TW202342519A/zh unknown
- 2023-02-16 WO PCT/EP2023/053940 patent/WO2023156549A1/en unknown
Also Published As
Publication number | Publication date |
---|---|
TW202342519A (zh) | 2023-11-01 |
WO2023156549A1 (en) | 2023-08-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6310895B2 (ja) | β−アミロイドペプチドのプロトフィブリル体に特異的なヒト化抗体 | |
AU2013211874B2 (en) | Humanized antibodies that recognize alpha-synuclein | |
CA2853531C (en) | Humanized antibodies that recognize alpha-synuclein | |
Manoutcharian et al. | Recombinant antibody fragments for neurodegenerative diseases | |
US20190383836A1 (en) | Early detection of glial cell activation in neurodegenerative or neuroinflammatory diseases | |
JP7109467B2 (ja) | タウに特異的に結合する結合分子 | |
JP2011527572A5 (es) | ||
AU2015279086A1 (en) | Antibodies and antigen-binding fragments that specifically bind to microtubule-associated protein tau | |
JP2020529473A5 (es) | ||
JP2020513806A5 (es) | ||
WO2019110571A1 (en) | Binding molecules that specifically bind to tau | |
JP2022529344A (ja) | 治療及び診断のための新規分子 | |
AR128540A1 (es) | Moléculas de unión anti-tdp-43 humanizadas y usos de las mismas | |
Chia et al. | Single-chain Fv antibodies for targeting neurodegenerative diseases | |
JPWO2021010712A5 (es) | ||
JP2023522212A (ja) | 治療用musk抗体 | |
JPWO2020234473A5 (es) | ||
US20240175869A1 (en) | Characterizing the binding interactions between musk and bmp receptors | |
KR20240031229A (ko) | 알파-시누클레인병증 치료용 항체 | |
US11274147B2 (en) | Binding molecules that specifically bind to tau | |
TW202417520A (zh) | 融合分子和治療免疫性疾病的方法 | |
IL303758A (en) | Antibody transport | |
AR116295A1 (es) | ANTICUERPOS ANTI-avb8 Y SUS COMPOSICIONES Y USOS |